Detalhe da pesquisa
1.
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
J Clin Oncol
; 36(23): 2405-2412, 2018 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29851546